VEGFA Antikörper (Biotin)

Produktnummer ABIN7539281

Dieses Anti-VEGFA-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von VEGFA in ELISA. Geeignet für Human.

Kurzübersicht für VEGFA Antikörper (Biotin) (ABIN7539281)

Target: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser VEGFA Antikörper ist konjugiert mit Biotin

Applikation: ELISA

Klon: 339-H2

Produktdetails anti-VEGFA Antikörper (Biotin)

Verwendungszweck: VEGF-A antibody

Spezifität: Chromosomal location:6p12

Aufreinigung: Protein A/G chromatography

Immunogen: Recombinant human VEGF189 protein [Cat# 300-094]

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA: Use at 1-5 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS, BSA (50x)

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Haltbarkeit: 24 months

Details zu VEGFA

Target: VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Andere Bezeichnung: VEGF-A

Hintergrund: VEGFA, VPF, VEGF, MVCD1,Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53 % amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Gen-ID: 7422

NCBI Accession: NM_001171626, NP_001165097

UniProt: P15692

Pathways: RTK Signalweg, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling